Genentech Licenses Prostate Cancer Drug From China-Based Jemincare
Executive Summary
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
You may also be interested in...
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC
The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker